Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Using a Modified Intensive Treat and Extend Regime to a Fixed Dosing Regimen

Next Previous
Trial Profile

An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Using a Modified Intensive Treat and Extend Regime to a Fixed Dosing Regimen

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Polypoidal choroidal vasculopathy
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Jul 2022 Primary endpoint (Mean Change in Best Corrected Visual Acuity (BCVA) has been met according to the results published in the British Journal of Ophthalmology
    • 01 Jul 2022 Results comparing the the efficacy of aflibercept using a personalised versus fixed regimen in treatment-naive participants with polypoidal choroidal vasculopathy (PCV) published in the British Journal of Ophthalmology
    • 01 Jan 2022 Results of Post hoc analysis assessing whether optical coherence tomography can determine polypoidal lesion perfusion in polypoidal choroidal vasculopathy eyes after 12 months of aflibercept monotherapy, published in the Retina
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top